Phase 2 data for ERLEADA® ▼(apalutamide) plus an

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate...

Related Keywords

Texas , United States , Belgium , Beerse , Region Flamande , San Antonio , American , Henar Hevia , Luca Dezzani , Exchange Commission , Janssen Research Development , Johnson , American Urological Association Annual Meeting , Steering Committee , Janssen Cilag International , None Of Janssen Cilag International , European Medicines Agency , Janssen Cilag International Nv Inc , Oral Presentation Session , Urological Association Annual Meeting , Steering Committee Chair , Chief Medical Officer , Surgical Oncology , Vice President , Medical Affairs , Solid Tumour , Johnson Innovative , Senior Director , Area Lead , Innovative Medicine , Cilag International , Janssen Pharmaceutica , Janssen Research , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Urological Association Annual , Cancer Factsheet , Risk Prostate Cancer , Very Challenging Disease , Adjuvant Treatment , Androgen Deprivation Therapy , Non Metastatic Prostate Cancer , Who Are , High Risk , Safety Study , Participants With High Risk , Radical Prostatectomy , Janssen Emea ,